DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hepatitis C, Chronic

Intervention: Peginterferon alfa-2b (Biological); Peginterferon alfa-2b (Biological); Ribavirin (Drug); Ribavirin (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: Merck Sharp & Dohme Corp.


This is an Australian, open-label, multicenter, randomized, double-blind clinical trial designed to assess the efficacy of combination therapy with pegylated interferon alfa-2b and ribavirin for 48 weeks versus 24 weeks in the treatment of chronic hepatitis C (treatment-nave genotype 3 subjects with high viral loads who have a METAVIR score of at least F1A2). The primary endpoint will be a sustained virological response defined by undetectable HCV RNA in serum at 24 weeks after completion of therapy.

Clinical Details

Official title: Phase IV Study of Tailored Therapy With Peg Interferon Alfa 2b and Ribavirin for Patients With Genotype 3 and High Viral Load. Genotype 3 Extended Treatment for HCV (GET-C Study)

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Sustained Virological Response (SVR), Defined by Undetectable HCV RNA in Serum at 24 Weeks After Completion of Therapy


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Comply with all current Australian Schedule of Pharmaceutical Benefits S100

eligibility criteria.

- Chronic hepatitis C genotype 3 infection with a viral load of at least 2 million

copies per mL.

- Able to give written informed consent.

- Understand and be able to adhere to the dosing and visit schedules.

- Compensated liver disease with the following minimum hematologic and biochemical


- Hemoglobin ≥120 g/L (females), ≥130 g/L (males)

- Platelets ≥100 x 10^9/L

- Neutrophil count ≥1. 5 x 10^9/L

- Creatinine clearance >50 mL/minute

- Thyroid stimulating hormone (TSH) within normal limits

- Serum hepatitis B surface antigen (HBsAg) and human immunodeficiency virus (HIV)


- Negative pregnancy test.

Exclusion Criteria:

- Suspected hypersensitivity to interferon, pegylated interferon alfa-2b, or ribavirin.

- Participation in any other investigational drug program within 30 days of the

screening visit for this protocol.

- Any cause of liver disease based on patient history and biopsy other than chronic

hepatitis C, including but not limited to: hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's disease, autoimmune hepatitis, alcoholic liver disease, drug-related liver disease.

- Hepatocellular carcinoma.

- Decompensated cirrhosis (ascites, history of encephalopathy or bleeding varices,

serum albumin <35 g/L, prothrombin time (PT) prolonged by greater than 3 sec).

- Significant cardiovascular dysfunction within the past 6 months (e. g., angina,

congestive heart failure, myocardial infarction, severe hypertension, or significant arrhythmia) or participants with an ECG showing clinically significant abnormalities.

- Immunologically-mediated disease, (e. g. inflammatory bowel disease), idiopathic

thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis).

- Hemophilia or any hemoglobinopathy, including but not limited to thalassemia major.

- Severe psychiatric condition, including major depression, a history of major

psychoses, current suicidal ideation, and/or suicidal attempts.

- Ongoing substance abuse, e. g. alcohol, I. V. drugs or inhalants that in the opinion of

the investigator would jeopardize the patient's ability to comply with study requirements.

- Clinically significant ophthalmological disorders.

- Treatment or recent treatment with immunosuppressive agents (excluding short-term

corticosteroid withdrawal) and immunosuppressed transplant recipients.

- Poorly controlled thyroid disease.

- Any other condition that in the opinion of the investigator would make the patient

unsuitable for enrolment, or could interfere with the patient participating in and completing the clinical trial program.

Locations and Contacts

Additional Information

Starting date: February 2005
Last updated: March 30, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017